Chemicals & Small Molecules

Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease.

Tarlatamab (AMG-757) is a first-in-class, high-affinity bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3), a protein primarily expressed in small-cell lung cancer (SCLC) with minimal expression in normal tissues. It has dissociation constants (KDs) of 0.64 nM and 0.50 nM for DLL3 in human and nonhuman primates (NHP), respectively, and 14.9 nM and 12 nM for CD3 in human and NHP, accordingly. As a pioneering HLE BiTE immuno-oncology therapy for DLL3-expression SCLC, tarlatamab shows promising potential for research in this area [1].

Gilvetmab, a potent caninized anti-PD-1 monoclonal antibody, effectively inhibits the interaction between PD-1 and its ligand PDL-1 [1].

Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.

Netakimab (BCD 085) is a humanized camel-derived monoclonal antibody targeting interleukin-17A, which can be used to study spondyloarthritis and plaque psoriasis.

Disitamab Vedotin (RC48-0) is a humanized monoclonal antibody that targets HER2 and can be utilized in creating antibody-drug conjugates (ADCs), specifically referred to as Disitamab Vedotin [1].

hBChE-IN-2 is a butyrylcholinesterase (BChE) inhibitor and cannabinoid receptor 2 (CB2R) agonist with neuroprotective activity for the study of Alzheimer's disease-like neurological disorders.

BLK degrader 1 is a selective B lymphoid tyrosine kinase (BLK) degrader with anticancer activity and can be used for cancer research.

RS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.